Generation of human myogenic progenitors from pluripotent stem cells for in vivo regeneration.
Hyunkee KimRita C R PerlingeiroPublished in: Cellular and molecular life sciences : CMLS (2022)
Muscular dystrophy encompasses a large number of heterogeneous genetic disorders characterized by progressive and devastating muscle wasting. Cell-based replacement strategies aimed at promoting skeletal muscle regeneration represent a candidate therapeutic approach to treat muscular dystrophies. Due to the difficulties of obtaining large numbers of stem cells from a muscle biopsy as well as expanding these in vitro, pluripotent stem cells (PSCs) represent an attractive cell source for the generation of myogenic progenitors, given that PSCs can repeatedly produce large amounts of lineage-specific tissue, representing an unlimited source of cells for therapy. In this review, we focus on the progress to date on different methods for the generation of human PSC-derived myogenic progenitor cells, their regenerative capabilities upon transplantation, their potential for allogeneic and autologous transplantation, as well as the specific challenges to be considered for future therapeutic applications.
Keyphrases
- pluripotent stem cells
- skeletal muscle
- cell therapy
- stem cells
- single cell
- insulin resistance
- muscular dystrophy
- mesenchymal stem cells
- induced apoptosis
- bone marrow
- endothelial cells
- stem cell transplantation
- multiple sclerosis
- cell cycle arrest
- gene expression
- wound healing
- climate change
- ultrasound guided
- cell proliferation
- copy number
- high dose
- endoplasmic reticulum stress
- dna methylation
- resistance training
- signaling pathway
- human health